Tag Archives: trials

Researchers Halt Trials of Promising Sickle Cell Treatment

Advertisement Continue reading the main story Supported by Continue reading the main story Researchers Halt Trials of Promising Sickle Cell Treatment Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible. Researchers working in the cellular and molecular therapeutics branch at the National Heart,… Read More »

China trials invasive new COVID bum test

Health authorities in China are mass testing residents for coronavirus – using anal swabs. Doctors claim the invasive procedure can be more effective in detecting the virus than nasal swabs, The Sun reports. China, where coronavirus first emerged just over a year ago, is currently experiencing its worst surge in cases since March. Outbreaks have… Read More »

Minorities Are Underrepresented in COVID-19 Clinical Trials

While clinical trials are currently underway to find treatment and vaccines for COVID-19, a new article published in The New England Journal of Medicine reveals that these trials lack sufficient representation of Black and indigenous people and people of color despite higher rates of coronavirus infection, COVID-19 hospitalization and death among these individuals, reports the… Read More »

WHO says the late-stage coronavirus trials don’t mean a vaccine is ‘nearly there’

Tony Potts, a 69-year-old retiree living in Ormond Beach, is examined by Dr. Bruce Rankin, Medical Director at Accel Research Sites, before Potts receives his first injection as a participant in a Phase 3 COVID-19 vaccine clinical trial sponsored by Moderna on August 4, 2020 in DeLand, Florida. Paul Hennessy | NurPhoto | Getty Images… Read More »

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen said on Monday it would buy back shares worth $ 5 billion, days after its stock slumped on the drugmaker’s announcement to end two Alzheimer’s disease trials. Biogen had lost more than $ 18 billion of its value last week after the company and partner Eisai ended two late-stage trials of their experimental Alzheimer’s… Read More »